Literature DB >> 1991806

Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links.

D Uebelhart1, A Schlemmer, J S Johansen, E Gineyts, C Christiansen, P D Delmas.   

Abstract

Pyridinoline (Pyr) and deoxypyridinoline (D-Pyr) are two cross-links of collagen molecules that are present in the extracellular matrix and released during its degradation. In contrast to the wide distribution of collagen, Pyr is present in bone and cartilage, but not in significant amounts in other connective tissues, and D-Pyr appears to be specific for bone tissue. Therefore, the urinary excretion of Pyr and D-Pyr might be a sensitive marker of bone matrix degradation. Using a specific high pressure liquid chromatography assay we have measured Pyr and D-Pyr cross-links in a 24-h and a fasting urine sample in 60 early postmenopausal women and 19 premenopausal women matched for age. Menopause induced a 62% increase in Fu Pyr (49.8 +/- 18.7 vs. 30.8 +/- 8.0 pmol/mumol creatinine; P less than 0.001) and an 82% increase in Fu D-Pyr (8.2 +/- 3.4 vs. 4.5 +/- 1.4 pmol/mumol creatinine; P less than 0.001). In 20 postmenopausal women on hormone replacement therapy, urinary Pyr and D-Pyr returned to premenopausal levels within 6 months, contrasting with unchanged levels during placebo treatment. The 24-h excretion of Pyr and D-Pyr was significantly lower than the fasting excretion, but was similarly decreased after hormone replacement therapy. Pyr and D-Pyr excretion measured in the same urinary sample were highly correlated (r = 0.85 for fasting and 0.83 for 24-h sampling), but correlations between fasting and 24-h values were weak (D-Pyr, r = 0.30; Pyr, r = 0.29; P less than 0.05 for both). Correlations between urinary cross-links and other markers of bone turnover (Fu hydroxyproline/creatinine and plasma osteocalcin) were significant but low (Pyr vs. osteocalcin, r = 0.29, P less than 0.05; Pyr vs. hydroxyproline, r = 0/.34; P less than 0.01; D-Pyr vs. osteocalcin, r = 0.39; P less than 0.01), except for D-Pyr vs. hydroxyproline (r = 0.24; P = 0.07), suggesting that these markers reflect different events of bone metabolism. Finally, a single measurement of the fasting excretion, but not of the 24-h excretion, of cross-links was significantly correlated (Pyr, r = 0.34; P less than 0.05; D-Pyr, r = -0.46; P less than 0.01), with the subsequent spontaneous rate of bone loss assessed by repeated measurements of the radial bone mineral content in 37 postmenopausal women.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1991806     DOI: 10.1210/jcem-72-2-367

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  55 in total

1.  The Urinary Excretion of Pyridinium Cross-links as Markers of Bone Meta stasisin Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1994-12-30       Impact factor: 4.239

Review 2.  Monitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women.

Authors:  E Dogan; C Posaci
Journal:  Postgrad Med J       Date:  2002-12       Impact factor: 2.401

3.  Biochemical markers of bone turnover predict bone loss in perimenopausal women but not in postmenopausal women-the Japanese Population-based Osteoporosis (JPOS) Cohort Study.

Authors:  M Iki; A Morita; Y Ikeda; Y Sato; T Akiba; T Matsumoto; H Nishino; S Kagamimori; Y Kagawa; H Yoneshima
Journal:  Osteoporos Int       Date:  2006-05-03       Impact factor: 4.507

4.  Serum levels of insulin-like growth factor (IGF); IGF-binding proteins-3, -4, and -5; and their relationships to bone mineral density and the risk of vertebral fractures in postmenopausal women.

Authors:  T Yamaguchi; M Kanatani; M Yamauchi; H Kaji; T Sugishita; D J Baylink; S Mohan; K Chihara; T Sugimoto
Journal:  Calcif Tissue Int       Date:  2006-01-06       Impact factor: 4.333

5.  Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease.

Authors:  Sarah A Bartram; Robert T Peaston; David J Rawlings; David Walshaw; Roger M Francis; Nick P Thompson
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

6.  Effect of the menopause and hormone replacement therapy on the carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen.

Authors:  C Hassager; J Risteli; L Risteli; C Christiansen
Journal:  Osteoporos Int       Date:  1994-11       Impact factor: 4.507

7.  Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women.

Authors:  C H Chesnut; S T Harris
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

8.  Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats.

Authors:  R B Kimble; J L Vannice; D C Bloedow; R C Thompson; W Hopfer; V T Kung; C Brownfield; R Pacifici
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

9.  Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN.

Authors:  M R Sowers; G A Greendale; I Bondarenko; J S Finkelstein; J A Cauley; R M Neer; B Ettinger
Journal:  Osteoporos Int       Date:  2003-04-11       Impact factor: 4.507

10.  Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption.

Authors:  R Eastell; S P Robins; T Colwell; A M Assiri; B L Riggs; R G Russell
Journal:  Osteoporos Int       Date:  1993-09       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.